AVTR: Avantor, Inc. Stock

by  •  • Comments Off on AVTR: Avantor, Inc. Stock

SIC 3826 – Laboratory Analytical Instruments

Valuation
Market Cap ($M) 11,908.99
Enterprise Value ($M) 15,702.89
Book Value ($M) 5,956.70
Book Value / Share 8.75
Price / Book 2.00
NCAV ($M) -4,011.20
NCAV / Share -5.89
Price / NCAV -2.97

Profitability (mra)
Return on Invested Capital (ROIC) 0.07
Return on Assets (ROA) 0.05
Return on Equity (ROE) 0.14

Liquidity (mrq)
Quick Ratio 0.70
Current Ratio 1.07

Balance Sheet (mrq) ($M)
Current Assets 2,146.60
Assets 12,114.50
Liabilities 6,157.80
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 6,783.60
Operating Income 638.20
Net Income 711.50
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 840.80
Cash from Investing 438.90
Cash from Financing -1,281.20

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
9 days ago 13G/A T. Rowe Price Investment Management, Inc.
02-13 13G/A Dodge & Cox
08-07 13G/A BlackRock, Inc. 10.80 59.97
2024-02-16 13G/A Price T Rowe Associates Inc /md/ 2.90 0.00
2024-02-13 13G/A Vanguard Group Inc 9.66 5.81

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-10-25 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-07-26 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-04-26 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 570,816 4,257,667 13.41
2025-02-20 517,398 3,573,884 14.48
2025-02-19 1,001,105 5,708,168 17.54
2025-02-18 1,198,059 9,646,977 12.42

(click for more detail)

Similar Companies
A – Agilent Technologies, Inc. AME – AMETEK, Inc.
BIO – Bio-Rad Laboratories, Inc. BIO.B – Bio-Rad Laboratories, Inc.


Financial data and stock pages provided by
Fintel.io